-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BeiGene has announced that the UK's National Institute for Health and Clinical Excellence (NICE), the UK's health technology assessment body, has published a final assessment document recommending Beyote ® Zebutinib for the treatment of adult patients with
NICE's decision marks the ® first and only conventional drug
WM is a rare B-cell lymphoma that makes up only 2%
Dr Shirley DSa, Consultant and Clinical Leader of the Centre for Hematology at the WM and Related Diseases Centre at University College London, said: "Beaux-Joy ® is a highly selective BTK inhibitor
In this evaluation, NICE believes that Baiyueze ® can be regarded as a "significant advance"
Dr Robert Mulrooney, General Manager of BeiGene, UK and Ireland, said: "I am delighted that NICE has listed NICE ® as an important treatment option for WM patients in England and Wales who meet the treatment standards, which will make WM patients in these areas the first people